Scholarlink

Purpose <p>To compare the therapeutic outcomes of intravitreal aflibercept injection (IVA) and reduced-fluence photodynamic therapy (rfPDT) for pachychoroid neovasculopathy (PNV) over 2 years.</p> Study design <p>Observational, retrospective case series. Single-center study.</p> Methods <p>This study involved 36 eyes of 36 patients with PNV. The IVA group comprised 18 eyes treated with IVA monotherapy (injection every 3 months followed by a pro re nata regimen), whereas the rfPDT group consisted of 18 eyes treated with rfPDT monotherapy. Post-treatment changes in best-corrected visual acuity (BCVA), macular atrophy (MA) area, central retinal thickness (CRT) and subfoveal choroidal thickness (SFCT) were compared between the 2 groups.</p> Results <p>The IVA group received 8.94&#xa0;±&#xa0;4.77 injections, whereas the rfPDT group received rfPDT 1.06 ± 0.24 times. The logMAR BCVA improved in both groups but did not differ between the 2 groups. The MA area increased from 0.163 ± 0.418&#xa0;mm<sup>2</sup> to 0.227 ± 0.480&#xa0;mm<sup>2</sup> (<i>P</i> = .024) and from 0.139 ± 0.402&#xa0;mm<sup>2</sup> to 0.597 ± 0.939&#xa0;mm<sup>2</sup> (<i>P</i> &lt; .001) in the IVA and rfPDT groups, respectively, with the rfPDT group showing a greater increase than the IVA group (<i>P</i> = .013). The CRT was reduced in both groups but did not differ between the 2 groups. The SFCT was reduced in both groups, but the reduction was higher in the rfPDT group than in the IVA group (<i>P</i> = .027). The factors affecting change in the MA area were the treatment method and patient age.</p> Conclusions <p>The increase in the MA area and the decrease in the SFCT were greater in the rfPDT group than in the IVA group for PNV, suggesting that IVA may be preferred over rfPDT for PNV treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Increased macular atrophy area with photodynamic therapy over intravitreal aflibercept at 2-year follow-up of pachychoroid neovasculopathy

  • 期刊论文

  • 发表日期：

    2025年6月21日

查看全文
  • Hirokazu Kojima,
  • Chieko Shiragami,
  • Ayana Yamashita,
  • Yukiko Miyoshi,
  • Rie Osaka,
  • Aoi Ono,
  • Kiyoshi Suzuma

摘要

Purpose

To compare the therapeutic outcomes of intravitreal aflibercept injection (IVA) and reduced-fluence photodynamic therapy (rfPDT) for pachychoroid neovasculopathy (PNV) over 2 years.

Study design

Observational, retrospective case series. Single-center study.

Methods

This study involved 36 eyes of 36 patients with PNV. The IVA group comprised 18 eyes treated with IVA monotherapy (injection every 3 months followed by a pro re nata regimen), whereas the rfPDT group consisted of 18 eyes treated with rfPDT monotherapy. Post-treatment changes in best-corrected visual acuity (BCVA), macular atrophy (MA) area, central retinal thickness (CRT) and subfoveal choroidal thickness (SFCT) were compared between the 2 groups.

Results

The IVA group received 8.94 ± 4.77 injections, whereas the rfPDT group received rfPDT 1.06 ± 0.24 times. The logMAR BCVA improved in both groups but did not differ between the 2 groups. The MA area increased from 0.163 ± 0.418 mm2 to 0.227 ± 0.480 mm2 (P = .024) and from 0.139 ± 0.402 mm2 to 0.597 ± 0.939 mm2 (P < .001) in the IVA and rfPDT groups, respectively, with the rfPDT group showing a greater increase than the IVA group (P = .013). The CRT was reduced in both groups but did not differ between the 2 groups. The SFCT was reduced in both groups, but the reduction was higher in the rfPDT group than in the IVA group (P = .027). The factors affecting change in the MA area were the treatment method and patient age.

Conclusions

The increase in the MA area and the decrease in the SFCT were greater in the rfPDT group than in the IVA group for PNV, suggesting that IVA may be preferred over rfPDT for PNV treatment.